BRPI0709612A2 - composto de fórmula i; método para o tratamento de um distúrbio no sistema nervoso central relacionado ou afetado pelo receptor histamina-3 em um paciente que necessita deste tratamento; método para a inibição do receptor h3; composição farmacêutica; e processo para a preparação de um composto de fórmula i - Google Patents

composto de fórmula i; método para o tratamento de um distúrbio no sistema nervoso central relacionado ou afetado pelo receptor histamina-3 em um paciente que necessita deste tratamento; método para a inibição do receptor h3; composição farmacêutica; e processo para a preparação de um composto de fórmula i Download PDF

Info

Publication number
BRPI0709612A2
BRPI0709612A2 BRPI0709612-7A BRPI0709612A BRPI0709612A2 BR PI0709612 A2 BRPI0709612 A2 BR PI0709612A2 BR PI0709612 A BRPI0709612 A BR PI0709612A BR PI0709612 A2 BRPI0709612 A2 BR PI0709612A2
Authority
BR
Brazil
Prior art keywords
methyl
benzimidazol
benzoyl
bipyrrolidine
pyrrolidin
Prior art date
Application number
BRPI0709612-7A
Other languages
English (en)
Portuguese (pt)
Inventor
Derek Cecil Cole
Magda Asselin
Joseph Raymond Stock
Albert Jean Robichaud
Ji-In Kim
William Ronald Solvibile
Jonathan Laird Gross
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of BRPI0709612A2 publication Critical patent/BRPI0709612A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Anesthesiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
BRPI0709612-7A 2006-03-15 2007-03-08 composto de fórmula i; método para o tratamento de um distúrbio no sistema nervoso central relacionado ou afetado pelo receptor histamina-3 em um paciente que necessita deste tratamento; método para a inibição do receptor h3; composição farmacêutica; e processo para a preparação de um composto de fórmula i BRPI0709612A2 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US78251306P 2006-03-15 2006-03-15
US60/782,513 2006-03-15
US85907906P 2006-11-15 2006-11-15
US60/859,079 2006-11-15
PCT/US2007/005776 WO2007108936A2 (en) 2006-03-15 2007-03-08 N-substituted-azacyclylamines as histamine-3 antagonists

Publications (1)

Publication Number Publication Date
BRPI0709612A2 true BRPI0709612A2 (pt) 2011-07-19

Family

ID=38353957

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0709612-7A BRPI0709612A2 (pt) 2006-03-15 2007-03-08 composto de fórmula i; método para o tratamento de um distúrbio no sistema nervoso central relacionado ou afetado pelo receptor histamina-3 em um paciente que necessita deste tratamento; método para a inibição do receptor h3; composição farmacêutica; e processo para a preparação de um composto de fórmula i

Country Status (11)

Country Link
US (1) US7820825B2 (enExample)
EP (1) EP1994022A2 (enExample)
JP (1) JP2009530274A (enExample)
AR (1) AR059905A1 (enExample)
AU (1) AU2007227681A1 (enExample)
BR (1) BRPI0709612A2 (enExample)
CA (1) CA2645731A1 (enExample)
MX (1) MX2008011791A (enExample)
PE (1) PE20071023A1 (enExample)
TW (1) TW200800958A (enExample)
WO (1) WO2007108936A2 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1972914A (zh) * 2004-03-31 2007-05-30 詹森药业有限公司 作为组胺h3受体配合体的非咪唑杂环化合物
JP2009530274A (ja) 2006-03-15 2009-08-27 ワイス ヒスタミン−３アンタゴニストとしてのｎ−置換−アザシクリルアミン化合物
EP2027086B1 (en) 2006-05-19 2011-11-16 Wyeth LLC N-benzoyl-pyrrolidin-3-ylamines as histamine-3 antagonists
KR101372941B1 (ko) * 2006-05-30 2014-03-14 얀센 파마슈티카 엔.브이. 히스타민 ｈ３ 수용체 조절제로서의 치환된 피리딜 아미드 화합물
US20080045507A1 (en) * 2006-06-29 2008-02-21 Allison Brett D Substituted benzamide modulators of the histamine h3 receptor
PE20081152A1 (es) 2006-10-06 2008-08-10 Wyeth Corp Azaciclilaminas n-sustituidas como antagonistas de histamina-3
TW200823204A (en) * 2006-10-17 2008-06-01 Arena Pharm Inc Biphenyl sulfonyl and phenyl-heteroaryl sulfonyl modulators of the histamine H3-receptor useful for the treatment of disorders related thereto
AR066721A1 (es) * 2007-05-24 2009-09-09 Wyeth Corp Derivados de benzo[d]imidazol-1-il, composicion farmaceutica, proceso de preparacion y uso.
AR067549A1 (es) 2007-07-16 2009-10-14 Wyeth Corp Compuesto de oxazol,tiazol e imidazol, composicion farmaceutica que lo comprende , proceso para la preparacion del compuesto , uso del compuesto y metodos para la inhibicion del receptor h3 y para el tratamiento de un trastorno cognitivo relacionado con o afectado por el receptor de histamina -3 (h3
US20090131417A1 (en) * 2007-11-20 2009-05-21 Letavic Michael A Substituted pyridyl amide compounds as modulators of the histamine h3 receptor
BRPI0820481A2 (pt) * 2007-11-20 2015-06-16 Janssen Pharmaceutica Nv Composotos cicloalquilóxi e heterocicloalquilóxi piridina como moduladores do receptor de h3 de histamina
SG176645A1 (en) * 2009-06-26 2012-01-30 Sanofi Sa Novel fumarate salts of a histamine h3 receptor antagonist
US8796247B2 (en) 2011-01-25 2014-08-05 Kissei Pharmaceutical Co., Ltd. Indole derivative, and pharmacologically acceptable salt thereof
HRP20180061T1 (hr) 2012-07-17 2018-02-23 Glaxosmithkline Intellectual Property (No. 2) Limited Indolkarbonitrili kao selektivni modulatori androgenskih receptora
HUE047988T2 (hu) 2015-06-09 2020-05-28 Abbvie Inc Nukleáris receptor modulátorok (ROR) gyulladásos és autoimmun betegségek kezelésére
EP3886854A4 (en) 2018-11-30 2022-07-06 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1416872A (en) 1972-03-10 1975-12-10 Wyeth John & Brother Ltd 4-aminoquinoline derivatives
US3933829A (en) * 1974-08-22 1976-01-20 John Wyeth & Brother Limited 4-Aminoquinoline derivatives
US4159331A (en) * 1978-05-05 1979-06-26 The Upjohn Company Antihypertensive 4-aminoquinolines
US4166853A (en) * 1978-05-05 1979-09-04 The Upjohn Company Antihypertensive 7-trifluoromethyl-4-aminoquinolones
CA2077897A1 (en) * 1990-04-13 1991-10-14 Robert G. Franz Substituted benzimidazoles
CN1052224C (zh) 1993-04-07 2000-05-10 大塚制药株式会社 哌啶衍生物、含有它的外周血管舒张剂及其应用
IL117149A0 (en) * 1995-02-23 1996-06-18 Schering Corp Muscarinic antagonists
US6034093A (en) * 1995-06-07 2000-03-07 Rhone-Poulenc Rorer Pharmaceuticals Inc. Substituted sulfonic acid N-[(aminoiminomethyl)phenylalkyl]-azaheterocyclylamide compounds
CA2287984A1 (en) 1997-05-01 1998-11-05 Gerald Floyd Smith Antithrombotic agents
US7375125B2 (en) * 1999-08-04 2008-05-20 Ore Pharmaceuticals, Inc. Melanocortin-4 receptor binding compounds and methods of use thereof
US6699873B1 (en) * 1999-08-04 2004-03-02 Millennium Pharmaceuticals, Inc. Melanocortin-4 receptor binding compounds and methods of use thereof
WO2001042224A1 (en) 1999-12-09 2001-06-14 Mitsubishi Pharma Corporation Carboxyamido derivatives
WO2001074773A2 (en) 2000-03-31 2001-10-11 Ortho Mcneil Pharmaceutical, Inc. Phenyl-substituted indoles as histamine h3-receptor antagonists
WO2002046168A1 (en) * 2000-12-07 2002-06-13 Astrazeneca Ab Therapeutic benzimidazole compounds
HN2002000156A (es) 2001-07-06 2003-11-27 Inc Agouron Pharmaceuticals Derivados de benzamida tiazol y composiciones farmaceuticas para inhibir la proliferacion de celulas y metodos para su utilización.
ATE447404T1 (de) 2002-03-29 2009-11-15 Novartis Vaccines & Diagnostic Substituierte benzazole und ihre verwendung als raf-kinase-hemmer
PT1603917E (pt) 2003-03-14 2011-02-04 Medigene Ag Compostos heterocíclicos imunomoduladores
CN1960969B (zh) * 2004-04-01 2012-03-28 伊莱利利公司 组胺h3受体药物、其制备方法及治疗用途
ATE381566T1 (de) * 2004-05-14 2008-01-15 Millennium Pharm Inc Verbindungen und verfahren zur inhibierung der mitotischen progression durch hemmung von aurorakinase
TW200602314A (en) 2004-05-28 2006-01-16 Tanabe Seiyaku Co A novel pyrrolidine compound and a process for preparing the same
US20060014733A1 (en) * 2004-07-19 2006-01-19 Pfizer Inc Histamine-3 agonists and antagonists
WO2006019833A1 (en) 2004-07-26 2006-02-23 Eli Lilly And Company Oxazole derivatives as histamine h3 receptor agents, preparation and therapeutic uses
US7705025B2 (en) 2004-08-23 2010-04-27 Eli Lilly And Company Histamine H3 receptor agents, preparation and therapeutic uses
CA2579889A1 (en) * 2004-09-09 2006-03-16 Astellas Pharma Inc. Thiazole derivatives having vap-1 inhibitory activity
UY29149A1 (es) 2004-10-07 2006-05-31 Boehringer Ingelheim Int Tiazolil-dihidro-indazoles
US7381732B2 (en) * 2004-10-26 2008-06-03 Bristol-Myers Squibb Company Pyrazolobenzamides and derivatives as factor Xa inhibitors
EP1848696A1 (en) * 2005-01-21 2007-10-31 Schering Corporation Imidazole and benzimidazole derivates useful as histamine h3 antagonists
JP2008537953A (ja) * 2005-04-15 2008-10-02 エラン ファーマシューティカルズ，インコーポレイテッド ブラジキニンｂ１受容体拮抗作用に有用な新規化合物
JP2009530274A (ja) 2006-03-15 2009-08-27 ワイス ヒスタミン−３アンタゴニストとしてのｎ−置換−アザシクリルアミン化合物
EP1996555A1 (en) 2006-03-20 2008-12-03 Glaxo Group Limited Compounds which potentiate ampa receptor and uses thereof in medicine
US20070238718A1 (en) 2006-04-06 2007-10-11 Matthias Grauert Thiazolyl-dihydro-indazole
EP2027086B1 (en) * 2006-05-19 2011-11-16 Wyeth LLC N-benzoyl-pyrrolidin-3-ylamines as histamine-3 antagonists
PE20081152A1 (es) 2006-10-06 2008-08-10 Wyeth Corp Azaciclilaminas n-sustituidas como antagonistas de histamina-3

Also Published As

Publication number Publication date
CA2645731A1 (en) 2007-09-27
US7820825B2 (en) 2010-10-26
AR059905A1 (es) 2008-05-07
PE20071023A1 (es) 2007-10-03
WO2007108936A3 (en) 2007-11-01
AU2007227681A1 (en) 2007-09-27
JP2009530274A (ja) 2009-08-27
MX2008011791A (es) 2008-09-25
EP1994022A2 (en) 2008-11-26
WO2007108936A2 (en) 2007-09-27
US20070219240A1 (en) 2007-09-20
TW200800958A (en) 2008-01-01

Similar Documents

Publication Publication Date Title
US7820825B2 (en) N-substituted-azacyclylamines as histamine-3 antagonists
WO2008045371A2 (en) N-substituted-azacyclylamines as histamine-3 antagonists
AU2008335880B2 (en) Hedgehog pathway antagonists and therapeutic applications thereof
EP0666858B1 (en) 5-arylindole derivatives and their use as serotonin (5-ht 1) agonists
CN101356174B (zh) 吲哚-3-基-羰基-螺-哌啶衍生物
WO2007136668A2 (en) N-benzoyl-and n-benzylpyrrolidin-3-ylamines as histamine-3 antagonists
CN110023291A (zh) 三环rho激酶抑制剂
WO2014092104A1 (ja) オキサジアゾール誘導体とその医薬用途
US20090023707A1 (en) Aminoalkylazole derivatives as histamine-3 antagonists
CA2688110A1 (en) Azacyclylbenzamide derivatives as histamine-3 antagonists
WO2010060703A1 (en) 3-(benzylamino)-pyrrolidine derivatives and their use as nk-3 receptor antagonists
EP2276731A1 (en) 2-sulfonylamino-4-heteroaryl butyramide antagonists of ccr10
CN101426778A (zh) 作为组胺-3拮抗剂的n-经取代-氮杂环基胺
US12540130B2 (en) Substituted pyrrolidine amides IV
KR101134255B1 (ko) 인돌
WO2010054968A1 (en) Quinazoline derivatives as nk3 receptor antagonists
KR20080094631A (ko) 칸나비노이드 ｃｂ1 수용체 길항제로서의 아졸 유도체
HK1151027A (en) Hedgehog pathway antagonists and therapeutic applications thereof

Legal Events

Date Code Title Description
B06G Technical and formal requirements: other requirements [chapter 6.7 patent gazette]

Free format text: PARA QUE A PETICAO NO 20090072525/RJ DE 28.07.09 SEJA ATENDIDA, APRESENTAR PROCURACAO ORIGINAL, OUCOPIA AUTENTICADA, DANDO PODERES PARA DESISTIR DO PEDIDO.

B15G Petition not considered as such [chapter 15.7 patent gazette]

Free format text: DESCONHECIDA A PETICAO NO 020090072525/RJ DE 28.07.09, EM VIRTUDE DO DISPOSTO NO ARTIGO 219 INCISOII DA LPI.

B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal acc. article 33 of ipl - extension of time limit for request of examination expired